Key Points
- Director Luke Evnin sold 331,005 shares of Werewolf Therapeutics between Jan. 2 and Jan. 16, generating roughly $193,843 in proceeds; his Jan. 16 sale of 38,782 shares left him with 2,159,860 shares valued at about $1,166,324 (a 1.76% decrease from that transaction).
- Werewolf Therapeutics (NASDAQ:HOWL) is trading near $0.56 with a market cap of $27.4 million and a 52‑week low of $0.53, while its 50‑day and 200‑day moving averages are $0.80 and $1.22, respectively.
- Analyst sentiment has softened after several downgrades and price-target cuts, leaving a consensus rating of Hold with a $3.75 target, and institutional investors now own about 64.84% of the stock.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the firm's stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $0.54, for a total transaction of $20,942.28. Following the transaction, the director directly owned 2,159,860 shares of the company's stock, valued at $1,166,324.40. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Luke Evnin also recently made the following trade(s):
- On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
- On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total transaction of $17,451.12.
- On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total value of $23,758.90.
- On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
- On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $15,053.58.
- On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $4,861.08.
- On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
- On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total value of $26,494.65.
- On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
- On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
Werewolf Therapeutics Stock Up 2.7%
Shares of NASDAQ:HOWL opened at $0.56 on Wednesday. The company's fifty day moving average is $0.80 and its 200-day moving average is $1.22. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 52 week low of $0.53 and a 52 week high of $2.38. The company has a market capitalization of $27.40 million, a PE ratio of -0.35 and a beta of 0.77.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. Equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Institutional Trading of Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth about $92,000. Susquehanna International Group LLP grew its position in shares of Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after buying an additional 13,439 shares during the period. Marshall Wace LLP bought a new stake in shares of Werewolf Therapeutics during the second quarter worth approximately $113,000. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the third quarter valued at approximately $304,000. Finally, Jane Street Group LLC bought a new position in Werewolf Therapeutics in the second quarter valued at approximately $409,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Bank of America reduced their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, November 18th. Citizens Jmp downgraded Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, December 19th. Wedbush lowered Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 price objective on the stock. in a research note on Friday, December 19th. HC Wainwright lowered their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a "buy" rating for the company in a research note on Friday, December 19th. Finally, Citigroup cut Werewolf Therapeutics from a "market outperform" rating to a "market perform" rating in a report on Friday, December 19th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $3.75.
Check Out Our Latest Stock Analysis on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
